Cargando…
Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer’s disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzhei...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660042/ https://www.ncbi.nlm.nih.gov/pubmed/33215083 http://dx.doi.org/10.1093/braincomms/fcaa132 |
_version_ | 1783608924747857920 |
---|---|
author | Laing, Krystal K Simoes, Sabrina Baena-Caldas, Gloria P Lao, Patrick J Kothiya, Milankumar Igwe, Kay C Chesebro, Anthony G Houck, Alexander L Pedraza, Lina Hernández, A Iván Li, Jie Zimmerman, Molly E Luchsinger, José A Barone, Frank C Moreno, Herman Brickman, Adam M |
author_facet | Laing, Krystal K Simoes, Sabrina Baena-Caldas, Gloria P Lao, Patrick J Kothiya, Milankumar Igwe, Kay C Chesebro, Anthony G Houck, Alexander L Pedraza, Lina Hernández, A Iván Li, Jie Zimmerman, Molly E Luchsinger, José A Barone, Frank C Moreno, Herman Brickman, Adam M |
author_sort | Laing, Krystal K |
collection | PubMed |
description | Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer’s disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzheimer's disease or directly promotes Alzheimer’s pathology is unclear. The purpose of this study was to examine the association between white matter hyperintensities and plasma levels of tau and to determine if white matter hyperintensities and tau levels interact to predict Alzheimer’s disease diagnosis. To confirm that cerebrovascular disease promotes tau pathology, we examined tau fluid biomarker concentrations and pathology in a mouse model of ischaemic injury. Three hundred ninety-one participants from the Alzheimer’s Disease Neuroimaging Initiative (74.5 ± 7.1 years of age) were included in this cross-sectional analysis. Participants had measurements of plasma total-tau, cerebrospinal fluid beta-amyloid, and white matter hyperintensities, and were diagnosed clinically as Alzheimer’s disease (n = 97), mild cognitive impairment (n = 186) or cognitively normal control (n = 108). We tested the relationship between plasma tau concentration and white matter hyperintensity volume across diagnostic groups. We also examined the extent to which white matter hyperintensity volume, plasma tau, amyloid positivity status and the interaction between white matter hyperintensities and plasma tau correctly classifies diagnostic category. Increased white matter hyperintensity volume was associated with higher plasma tau concentration, particularly among those diagnosed clinically with Alzheimer’s disease. Presence of brain amyloid and the interaction between plasma tau and white matter hyperintensity volume distinguished Alzheimer’s disease and mild cognitive impairment participants from controls with 77.6% and 63.3% accuracy, respectively. In 63 Alzheimer’s Disease Neuroimaging Initiative participants who came to autopsy (82.33 ± 7.18 age at death), we found that higher degrees of arteriosclerosis were associated with higher Braak staging, indicating a positive relationship between cerebrovascular disease and neurofibrillary pathology. In a transient middle cerebral artery occlusion mouse model, aged mice that received transient middle cerebral artery occlusion, but not sham surgery, had increased plasma and cerebrospinal fluid tau concentrations, induced myelin loss, and hyperphosphorylated tau pathology in the ipsilateral hippocampus and cerebral hemisphere. These findings demonstrate a relationship between cerebrovascular disease, operationalized as white matter hyperintensities, and tau levels, indexed in the plasma, suggesting that hypoperfusive injury promotes tau pathology. This potential causal association is supported by the demonstration that transient cerebral artery occlusion induces white matter damage, increases biofluidic markers of tau, and promotes cerebral tau hyperphosphorylation in older-adult mice. |
format | Online Article Text |
id | pubmed-7660042 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-76600422020-11-18 Cerebrovascular disease promotes tau pathology in Alzheimer’s disease Laing, Krystal K Simoes, Sabrina Baena-Caldas, Gloria P Lao, Patrick J Kothiya, Milankumar Igwe, Kay C Chesebro, Anthony G Houck, Alexander L Pedraza, Lina Hernández, A Iván Li, Jie Zimmerman, Molly E Luchsinger, José A Barone, Frank C Moreno, Herman Brickman, Adam M Brain Commun Original Article Small vessel cerebrovascular disease, visualized as white matter hyperintensities on T2-weighted magnetic resonance imaging, contributes to the clinical presentation of Alzheimer’s disease. However, the extent to which cerebrovascular disease represents an independent pathognomonic feature of Alzheimer's disease or directly promotes Alzheimer’s pathology is unclear. The purpose of this study was to examine the association between white matter hyperintensities and plasma levels of tau and to determine if white matter hyperintensities and tau levels interact to predict Alzheimer’s disease diagnosis. To confirm that cerebrovascular disease promotes tau pathology, we examined tau fluid biomarker concentrations and pathology in a mouse model of ischaemic injury. Three hundred ninety-one participants from the Alzheimer’s Disease Neuroimaging Initiative (74.5 ± 7.1 years of age) were included in this cross-sectional analysis. Participants had measurements of plasma total-tau, cerebrospinal fluid beta-amyloid, and white matter hyperintensities, and were diagnosed clinically as Alzheimer’s disease (n = 97), mild cognitive impairment (n = 186) or cognitively normal control (n = 108). We tested the relationship between plasma tau concentration and white matter hyperintensity volume across diagnostic groups. We also examined the extent to which white matter hyperintensity volume, plasma tau, amyloid positivity status and the interaction between white matter hyperintensities and plasma tau correctly classifies diagnostic category. Increased white matter hyperintensity volume was associated with higher plasma tau concentration, particularly among those diagnosed clinically with Alzheimer’s disease. Presence of brain amyloid and the interaction between plasma tau and white matter hyperintensity volume distinguished Alzheimer’s disease and mild cognitive impairment participants from controls with 77.6% and 63.3% accuracy, respectively. In 63 Alzheimer’s Disease Neuroimaging Initiative participants who came to autopsy (82.33 ± 7.18 age at death), we found that higher degrees of arteriosclerosis were associated with higher Braak staging, indicating a positive relationship between cerebrovascular disease and neurofibrillary pathology. In a transient middle cerebral artery occlusion mouse model, aged mice that received transient middle cerebral artery occlusion, but not sham surgery, had increased plasma and cerebrospinal fluid tau concentrations, induced myelin loss, and hyperphosphorylated tau pathology in the ipsilateral hippocampus and cerebral hemisphere. These findings demonstrate a relationship between cerebrovascular disease, operationalized as white matter hyperintensities, and tau levels, indexed in the plasma, suggesting that hypoperfusive injury promotes tau pathology. This potential causal association is supported by the demonstration that transient cerebral artery occlusion induces white matter damage, increases biofluidic markers of tau, and promotes cerebral tau hyperphosphorylation in older-adult mice. Oxford University Press 2020-08-19 /pmc/articles/PMC7660042/ /pubmed/33215083 http://dx.doi.org/10.1093/braincomms/fcaa132 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Laing, Krystal K Simoes, Sabrina Baena-Caldas, Gloria P Lao, Patrick J Kothiya, Milankumar Igwe, Kay C Chesebro, Anthony G Houck, Alexander L Pedraza, Lina Hernández, A Iván Li, Jie Zimmerman, Molly E Luchsinger, José A Barone, Frank C Moreno, Herman Brickman, Adam M Cerebrovascular disease promotes tau pathology in Alzheimer’s disease |
title | Cerebrovascular disease promotes tau pathology in Alzheimer’s disease |
title_full | Cerebrovascular disease promotes tau pathology in Alzheimer’s disease |
title_fullStr | Cerebrovascular disease promotes tau pathology in Alzheimer’s disease |
title_full_unstemmed | Cerebrovascular disease promotes tau pathology in Alzheimer’s disease |
title_short | Cerebrovascular disease promotes tau pathology in Alzheimer’s disease |
title_sort | cerebrovascular disease promotes tau pathology in alzheimer’s disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660042/ https://www.ncbi.nlm.nih.gov/pubmed/33215083 http://dx.doi.org/10.1093/braincomms/fcaa132 |
work_keys_str_mv | AT laingkrystalk cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT simoessabrina cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT baenacaldasgloriap cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT laopatrickj cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT kothiyamilankumar cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT igwekayc cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT chesebroanthonyg cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT houckalexanderl cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT pedrazalina cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT hernandezaivan cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT lijie cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT zimmermanmollye cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT luchsingerjosea cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT baronefrankc cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT morenoherman cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT brickmanadamm cerebrovasculardiseasepromotestaupathologyinalzheimersdisease AT cerebrovasculardiseasepromotestaupathologyinalzheimersdisease |